Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations
Cheng H, Callis S, Yu E, Delacroix S, Sokolova A, Tangen C, Lerner S, Dorff T, Lin D. Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. European Urology Focus 2025 PMID: 41354605, DOI: 10.1016/j.euf.2025.11.011.Peer-Reviewed Original ResearchLocalized high-risk prostate cancerHigh-risk prostate cancerPhase 2 studyNeoadjuvant carboplatinBRCA1/2 mutationsProstate cancerPathologic complete response rateComplete response rateGermline BRCA1/2 mutationsPhase 2 trialSurvival outcomesChemotherapy agentsClinical trialsResponse rateCarboplatinSWOGCancerMutationsBRCA1/2ChemotherapyPatientsGermlineEndpointSurvivalTrialsSystemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.
Sadeghi S, Lara P, Necchi A, Gill P, Flaig T, Lerner S, Aron M, Daneshmand S. Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncology Practice 2025, op2500464. PMID: 41252668, DOI: 10.1200/op-25-00464.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerNeoadjuvant systemic therapyPathological complete responseClinical complete responseSystemic therapyOverall survivalCarcinoma in situRadical cystectomyComplete responseBladder cancerSurgical volumeNeoadjuvant cisplatin-based chemotherapyPatients treated with RCMuscle-invasive urothelial carcinomaCohort analysisOutcomes of systemic therapyStandard-of-care treatmentImpact of surgical volumeBladder preservation strategiesPerioperative systemic therapyAdjuvant systemic therapyMuscle-invasive diseaseCisplatin-based chemotherapyMedian Follow-UpNational Cancer DatabaseBladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer
Dyrskjøt L, Black P, Lerner S, Theodorescu D. Bladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer. Bladder Cancer 2025, 11: 23523735251384859. PMID: 41140788, PMCID: PMC12552773, DOI: 10.1177/23523735251384859.Peer-Reviewed Original ResearchIntermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Li R, Hensley P, Babjuk M, Bukavina L, Psutka S, Lerner S, O'Donnell M, Lotan Y, Bree K, Redorta J, McConkey D, Lee B, Mariappan P, Mertens L, Soloway M, Svatek R, Tan W, Williams S, Gupta S, Buckley R, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. European Urology Oncology 2025, 8: 1685-1695. PMID: 41076366, DOI: 10.1016/j.euo.2025.08.003.Peer-Reviewed Original ResearchConceptsInternational Bladder Cancer GroupNon-muscle-invasive bladder cancerBladder cancer groupClinical trial designTreatment burdenPatient-reported outcomesCancer groupTrial designAdjuvant intravesical treatmentPatient careDelphi processClinical careRisk scoring systemCancer expertsRandomized Controlled StudyClinical trial developmentStandard of careCareIntravesical treatmentPerioperative chemotherapyTransurethral resectionIndolent courseLG tumorsBladder tumorsActive surveillance69Testing cabozantinib with or without atezolizumab in patients with advanced papillary kidney cancer (NCT05411081)
Maughan B, Plets M, Pal S, Ged Y, Tangen C, Vaishampayan U, Lerner S, Desai A. 69Testing cabozantinib with or without atezolizumab in patients with advanced papillary kidney cancer (NCT05411081). The Oncologist 2025, 30: oyaf276.070. PMCID: PMC12509857, DOI: 10.1093/oncolo/oyaf276.070.Peer-Reviewed Original ResearchProgression-free survivalCombination therapySingle-arm studyDose reductionImmune therapyRandomized studyComparison of progression-free survivalClinical trialsClinical valueDose reductions of cabozantinibRandomized phase II clinical trialCombination immune therapyObjective response rateUpfront combination therapyPhase II clinical trialSoft tissue tumor samplesII clinical trialsClear cell RCCStandard of careDisease specific treatmentSingle agent studiesDose delaysSequential therapyOverall survivalCell RCCCisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy
Fazili A, Jazayeri S, Rose K, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson M, Grass G, Xu H, Spiess P, Gilbert S, Sexton W, Zemp L, Pessoa R, Poch M, Lerner S, Li R. Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy. BJU International 2025, 137: 181-188. PMID: 40932312, DOI: 10.1111/bju.16895.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerCisplatin-ineligible patientsEvent-free survivalCIS patientsOncological outcomesOverall survivalRadical cystectomyBladder cancerCis groupRetrospective comparisonMedian event-free survivalNon-cancer-related deathsAlternative chemotherapy regimensImmediate radical cystectomyMedian overall survivalKaplan-Meier methodLog-rank testTertiary care centreStandard-of-careLong-term survivalMulti-institutional dataCisplatin-eligibleRecurrence-freeChemotherapy regimensRandomised controlled trialsEnd Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Necchi A, Galsky M, Dizman N, Aggen D, Agarwal N, Al-Ahmadie H, Apolo A, Ballas L, Bangs R, Black P, Brausi M, Brembilla G, Cheng L, Chiti A, Cimadamore A, Colecchia M, Daneshmand S, Di Stasi S, Efstathiou J, Filicevas A, Geynisman D, Grivas P, Gupta S, Iasonos A, James N, Lerner S, Loriot Y, Makaroff L, Maluf F, Moschini M, Ostrovnaya I, Pal S, Plimack E, Prakash G, Psutka S, Rosenberg J, Sadeghi S, Schmidt B, Schwartz L, Sonpavde G, St Laurent M, Ye D, Spiess P, Kamat A. End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. Journal Of Clinical Oncology 2025, 43: 3536-3544. PMID: 40934451, PMCID: PMC12431632, DOI: 10.1200/jco-25-01608.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerInternational Bladder Cancer GroupClinical complete responseEvent-free survivalEvolving treatment landscapeBladder cancerDefinition of clinical complete responseConsensus definitionBladder-sparing treatmentCoprimary end pointsHigh-grade malignancyBladder cancer groupClinically meaningful benefitOrgan preservation strategiesEarly-phase studiesMultidisciplinary consensus panelIntention-to-treat approachBladder preservationSurgical consolidationComplete responseGenitourinary tumorsMetastatic diseaseUrine cytologyPerioperative strategiesPerioperative trialsLow-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies
Wen L, Miyagi H, Spiess P, Yu A, Mendelsohn C, Tan W, Psutka S, Lerner S, Cheng L, Dyrskjøt L, Meeks J, Shariat S, Gontero P, Pradere B, Steinberg G, Kamat A, Li R. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nature Reviews Urology 2025, 22: 846-861. PMID: 40931081, DOI: 10.1038/s41585-025-01072-0.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerTreatment strategiesNovel treatment strategiesValidation of novel biomarkersFollow-up monitoringSurveillance cystoscopyFavorable prognosisOffice cystoscopyTargeted therapyImmunomodulatory agentsTreatment optionsEmergency therapyDisease behaviorDrug delivery systemsMolecular landscapeTherapyTreatment burdenStage progressionNovel biomarkersPatientsPatient outcomesDisease biologyHealth care costsProteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer
Holt M, Dou Y, Young M, Saltzman A, Anurag M, Lei J, Jain A, Leng M, Kim B, Dobrolecki L, Faucher S, Savage S, Wang C, Shi Z, Villanueva H, Kremers K, Drinnon K, Castro P, Ittmann M, Khatani M, Kim S, Ellis M, Zhang B, Malovannaya A, Lerner S. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Reports Medicine 2025, 6: 102255. PMID: 40749681, PMCID: PMC12432383, DOI: 10.1016/j.xcrm.2025.102255.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerIsoform-level analysisBladder cancerMulti-omics clusteringBenefit of combination therapyFamily proteinsPhosphoproteomic dataBiomarkers of chemosensitivityProteogenomic characterizationJAK/STAT pathwayProtein abundanceAssociated with chemoresistanceWnt signalingPD-L1ProteinCombination therapyChemoresistance mechanismsMolecular subtypesChemotherapy sensitivityChemoresistanceTherapeutic opportunitiesATAD1SubtypesGenomeCancerAndrogen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocks